Page last updated: 2024-11-10

calyculin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

calyculin A: RN given refers to (5S-(5alpha(2R*(1S*,3S*,4S*,5R*,6R*,7E,9E,11E,13Z),3R*),7beta(E(S*)),*beta,9alpha))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5311365
CHEMBL ID430266
MeSH IDM0164392

Synonyms (31)

Synonym
101932-71-2
calyculin a
calyculin
calyculin a from discodermia calyx, >=90% (hplc), solid
DB02860
(-)-calyculin a
l-ribonamide, n-((3s)-3-(4-((1e)-3-((2r,3r,5r,7s,8s,9r)-2-((1s,3s,4s,5r,6r,7e,9e,11e,13z)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyl-7,9,11,13-tetradecatetraenyl)-9-hydroxy-4,4,8-trimethyl-3-(phosphonooxy)-1,6-dioxaspiro(4.5)dec-7-yl)-1-prope
ccris 3706
CHEMBL430266 ,
calyculin-a
bdbm50110681
7d07u14tk3 ,
unii-7d07u14tk3
calyculin a from discodermia calyx
n-[(3s)-[4-(1e)-3-[(2r,3r,4r,7s,8s,9r)-2-[(1s,3s,4s,5r,7e,9e,11e,13z)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyl-7,9,11,13-tetradecatetraenyl]-9-hydroxy-4,4,8-trimethyl-3-(phosphonooxy)-1,6-dioxaspiro[4.5]dec-7-yl]-1-propenyl]-2-oxazoly]butyl
calyculin a [mi]
HB0165
c10h12n5o5ps.c6h15n
(r)-adenosine,cyclic3',5'-(hydrogenphosphorothioate)triethylammonium
AKOS024456533
mfcd06795864
HY-18983
CS-5406
J-000525
calyculin a from discodermia calyx, >=90% (hplc)
(2r,3r,5r,7s,8s,9r)-2-[(1s,3s,4s,5r,6r,7e,9e,11e,13z)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraen-1-yl]-7-[(2e)-3-{2-[(1s)-3-{[4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanoyl]amino}-1-methylpropyl]-1,3-oxazol-4-yl
DTXSID00883097
Q27093822
[(2r,3r,5r,7r,8s,9s)-2-[(1s,3s,4s,5r,6r,7e,9e,11e,13z)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraenyl]-9-[(e)-3-[2-[(2s)-4-[[(2s,3s,4s)-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanoyl]amino]butan-2-yl]-1,3-oxazol-4
(2r,3r,5r,7s,8s,9r)-2-((1s,3s,4s,5r,6r,7e,9e,11e,13z)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraen-1-yl)-7-((e)-3-(2-((s)-4-((2s,3s,4s)-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanamido)butan-2-yl)oxazol-4-yl)allyl
BEA93271

Research Excerpts

Overview

Calyculin A (Cal A) is a serine/threonine phosphatase inhibitor. It is capable of inducing apoptosis in cancer cells.

ExcerptReferenceRelevance
"Calyculin A (Cal A) is a serine/threonine phosphatase inhibitor that is capable of inducing apoptosis in cancer cells. "( Calyculin A causes sensitization to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by ROS-mediated down-regulation of cellular FLICE-inhibiting protein (c-FLIP) and by enhancing death receptor 4 mRNA stabilization.
Kwon, TK; Min, KJ; Woo, SM, 2012
)
3.26

Effects

ExcerptReferenceRelevance
"Calyculin A has been extensively used as a specific inhibitor of protein phosphatases."( Calyculin A and outward K+ channel currents in rat tail artery smooth muscle cells.
Hanna, ST; Wang, R, 2002
)
2.48

Actions

ExcerptReferenceRelevance
"Calyculin A is known to inhibit the type-1 and type-2A phosphatases. "( Calyculin A causes the activation of histone H1 kinase and condensation of chromosomes in unfertilized sea urchin eggs independently of the maturation-promoting factor.
Fusetani, N; Seki, Y; Tosuji, H, 2003
)
3.2

Treatment

Calyculin A (50 nM) treatment for 30 min before the 48-h harvest of mitogen-stimulated human PBL is optimum for the formation of suitable chromosome morphology. The treatment did not produce a significant increase in the background of chromosomal aberrations.

ExcerptReferenceRelevance
"Calyculin A treatment prevents inhibitor and PD mutant induced dephosphorylation and reverts LRRK2 to a lesser ubiquitinated species, thus directly implicating phosphatase activity in LRRK2 ubiquitination."( LRRK2 dephosphorylation increases its ubiquitination.
Langston, JW; Molitor, TP; Nichols, RJ; Zhao, J, 2015
)
1.14
"Calyculin A-treatment markedly increased the expression of TNF-alpha mRNA and enhanced the phosphorylation level of Akt (Ser473) in these cells. "( PI3K/Akt mediates expression of TNF-alpha mRNA and activation of NF-kappaB in calyculin A-treated primary osteoblasts.
Li, Z; Mi, X; Qin, K; Qiu, L; Yang, D; Zhang, L; Zhu, L, 2008
)
2.02
"Calyculin A (50 nM) treatment for 30 min before the 48-h harvest of mitogen-stimulated human PBL is optimum for the formation of suitable chromosome morphology necessary to assess structural chromosome aberrations induced by exposure to radiation using the chemical induced-PCC assay."( Optimization of calyculin A-induced premature chromosome condensation assay for chromosome aberration studies.
Blakely, WF; Miura, T, 2011
)
1.44
"Calyculin A treatment induced cell cycle arrest in MDA-MB-468 and MCF-7 breast cancer cells."( The Discodermia calyx toxin calyculin a enhances cyclin D1 phosphorylation and degradation, and arrests cell cycle progression in human breast cancer cells.
Brautigan, DL; Edelson, JR, 2011
)
1.38
"Calyculin A (10 mol/L) pretreatment further enhanced Ang-II, and PMA induced increase of calcium sensitivity, yet weakened the 8Br-cGMP-induced decrease of calcium sensitivity."( The role of calcium desensitization in vascular hyporeactivity and its regulation after hemorrhagic shock in the rat.
Liu, L; Xu, J, 2005
)
1.05
"In calyculin A-treated cells phosphodiesterase activity was also strongly inhibited by IBMX, but because of the stimulating effect of calyculin A, the activity remaining was still 55% of that found in control homogenates."( Involvement of calyculin A inhibitable protein phosphatases in the cyclic AMP signal transduction pathway of mouse corticotroph tumour (AtT20) cells.
Ang, KL; Antaraki, A; Antoni, FA, 1997
)
1.16
"Calyculin A treatment resulted in comparable changes with 10fold lower concentrations than okadaic acid."( Inhibitors of ser/thr phosphatases 1 and 2A induce apoptosis in pituitary GH3 cells.
Marwitz, J; Opitz, R; Quentin, I; Ritz, V; Steinfelder, HJ; Tergau, F; von Zezschwitz, C; Weichert, J, 1997
)
1.02
"The calyculin A treatment did not produce a significant increase in the background of chromosomal aberrations or modify the yield of chromosomal aberrations scored after exposure to X-rays."( A simple method for simultaneous interphase-metaphase chromosome analysis in biodosimetry.
Durante, M; Furusawa, Y; Gotoh, E, 1998
)
0.78
"Treatment with calyculin A, but not with okadaic acid, increased TDP-43 phosphorylation at Ser379, Ser403/404, and Ser409/410 in cultured cells."( Protein Phosphatase 1 dephosphorylates TDP-43 and suppresses its function in tau exon 10 inclusion.
Chen, F; Gong, CX; Gu, J; Hu, W; Iqbal, K; Liu, F; Miao, S; Wang, W; Wu, F, 2018
)
0.82
"Treatment with calyculin A (50 nM) for 15 and 30 min resulted in 11.3 ± 2.7 and 9.9 ± 1.6-fold increases in the frequency of G(2) /M-PCC cells with extended length chromosomes compared with the 60-min treated group over a broad dose range (0 to 20 Gy), respectively."( Optimization of calyculin A-induced premature chromosome condensation assay for chromosome aberration studies.
Blakely, WF; Miura, T, 2011
)
1.05
"Cotreatment with calyculin A and LIF markedly increased STAT3 S727 phosphorylation, without affecting the increase in the nuclear fraction of STAT3 phosphorylated on Y705."( Calyculin A reveals serine/threonine phosphatase protein phosphatase 1 as a regulatory nodal point in canonical signal transducer and activator of transcription 3 signaling of human microvascular endothelial cells.
Booz, GW; Chidiac, R; Kurdi, M; Zgheib, C; Zouein, FA, 2012
)
2.15
"Pre-treatment with calyculin A abolished the component of the Ca(2+) rise associated with activation of CRAC uptake and inhibited Mn(2+) entry, consistent with a requirement of phosphatase activity for activation of the pathway."( Inhibition by calyculin A and okadaic acid of the Ca(2+) release-activated Ca(2+) entry pathway in rat basophilic leukemia cells: evidence for regulation by type 1/2A serine/threonine phosphatase activity.
Evans, NE; Forth, MK; Mason, MJ; Simpson, AK, 2005
)
1.01
"Treatment with calyculin A also prevented hypoxic inhibition of NHE activity."( The effect of O2 tension on pH homeostasis in equine articular chondrocytes.
Browning, JA; Fairfax, TP; Gibson, JS; Milner, PI; Wilkins, RJ, 2006
)
0.67
"Pretreatment with calyculin A, an inhibitor of protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A), blocked emetine-induced alternative splicing in contrast to okadaic acid, a specific inhibitor of PP2A in cells, demonstrating a PP1-mediated mechanism."( Emetine regulates the alternative splicing of Bcl-x through a protein phosphatase 1-dependent mechanism.
Boon-Unge, K; Govitrapong, P; Yu, Q; Zhou, A; Zhou, J; Zou, T, 2007
)
0.66
"Pretreatment with calyculin A completely prevented the stimulation of cyclic AMP formation by cholera toxin even in the presence of 0.5 mM isobutylmethylxanthine (IBMX) and 0.1 mM rolipram."( Involvement of calyculin A inhibitable protein phosphatases in the cyclic AMP signal transduction pathway of mouse corticotroph tumour (AtT20) cells.
Ang, KL; Antaraki, A; Antoni, FA, 1997
)
0.97
"Treatment with calyculin A produced a high fraction of chromosome condensation in different phases of the cell cycle. "( A simple method for simultaneous interphase-metaphase chromosome analysis in biodosimetry.
Durante, M; Furusawa, Y; Gotoh, E, 1998
)
0.65
"Pretreatment with calyculin A (5 nm), an inhibitor of protein phosphatase-1 (PP1) and protein phosphatase 2A (PP2A) blocked ceramide-induced alternative splicing in contrast to okadaic acid (10 nm), a specific inhibitor of PP2A at this concentrations in cells, demonstrating a PP1-mediated mechanism."( De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1.
Chalfant, CE; Hannun, YA; Obeid, LM; Ogretmen, B; Pinkerman, RL; Rathman, K; Wood, RE, 2002
)
0.64
"Treatment with calyculin A (CalyA), which causes condensation of cortical cytoskeleton, inhibited CCE."( Calcium influx factor from cytochrome P-450 metabolism and secretion-like coupling mechanisms for capacitative calcium entry in corneal endothelial cells.
Bonanno, JA; Xie, Q; Zhai, C; Zhang, Y, 2002
)
0.65

Toxicity

ExcerptReferenceRelevance
" Mcyst hepatotoxicity is therefore a direct consequence of PP inhibition in hepatocytes, the loss of sinusoidal integrity following from the primary toxic insult to the hepatocyte."( Differential toxicity of the protein phosphatase inhibitors microcystin and calyculin A.
Berndt, N; Deleve, LD; Govindarajan, S; Maddatu, T; Runnegar, MT, 1995
)
0.52

Dosage Studied

ExcerptRelevanceReference
" Rnd1 inhibited GTPgammaS-induced tension without shifting the dose-response curves to GTPgammaS."( The Rho-related protein Rnd1 inhibits Ca2+ sensitization of rat smooth muscle.
Cario-Toumaniantz, C; Chardin, P; Loirand, G; Pacaud, P, 1999
)
0.3
" PP activity was still 95% inhibited 7 days after dosing in skates given 125 microg/kg microcystin."( Hepatic toxicity and persistence of ser/thr protein phosphatase inhibition by microcystin in the little skate Raja erinacea.
Ballatori, N; Boyer, JL; Crawford, JM; Runnegar, M; Seward, DJ, 1999
)
0.3
"U937-ASPI3K exhibited an enhanced apoptotic susceptibility to lower dosage of irradiation, which could not be blocked by protein synthesis inhibitor."( [The relationship between ATM gene silence inducing apoptosis susceptibility and abnormal CDK activity].
Gong, JP; Hu, JB; Liu, WL; Sun, HY; Tang, Y; Zhou, JF, 2003
)
0.32
"5-2 Gy dosage of gamma-radiation as well as incubation of cells with calyculin A, a potent inhibitor of protein phosphatase 1 and 2A, both elevate dCK activity without changing the level of dCK protein."( Activation of deoxycytidine kinase by gamma-irradiation and inactivation by hyperosmotic shock in human lymphocytes.
Csapo, Z; Keszler, G; Safrany, G; Sasvari-Szekely, M; Spasokoukotskaja, T; Staub, M; Talianidis, I, 2003
)
0.55
" The cumulative dose-response curve of SMA to NE and Ca2+ after shock was shifted to the right."( The role of calcium desensitization in vascular hyporeactivity and its regulation after hemorrhagic shock in the rat.
Liu, L; Xu, J, 2005
)
0.33
" Dose-response curves to the Ca(2+) ionophore A-23187 and to the calmodulin/myosin light chain kinase inhibitor W-7 served to study Ca(2+)-dependent pathways."( Both Ca2+ -dependent and -independent pathways are involved in rat hepatic stellate cell contraction and intrahepatic hyperresponsiveness to methoxamine.
Bisschops, R; Cassiman, D; Fevery, J; Laleman, W; Nevens, F; Roskams, T; Severi, T; Van Landeghem, L; Van Pelt, J; Vander Elst, I; Zeegers, M, 2007
)
0.34
" GNE1023 treatment decreased the phosphorylation and stability of LRRK2 in expression systems and endogenous LRRK2 in A549 cells and in mouse dosing studies."( LRRK2 dephosphorylation increases its ubiquitination.
Langston, JW; Molitor, TP; Nichols, RJ; Zhao, J, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)0.00090.00053.49849.7600AID164502; AID164505
Serine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)IC50 (µMol)0.21090.00000.15921.7800AID200711; AID200712; AID200713; AID200714; AID200715; AID200716; AID200717; AID200718; AID200719; AID200720
Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B Gallus gallus (chicken)IC50 (µMol)0.00320.00010.41982.9000AID164507; AID164675; AID200735
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (39)

Processvia Protein(s)Taxonomy
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
MAPK cascadeSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
blastocyst developmentSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
glycogen metabolic processSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
protein dephosphorylationSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
spermatogenesisSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
neuron differentiationSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
circadian regulation of gene expressionSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
regulation of circadian rhythmSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
entrainment of circadian clock by photoperiodSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
regulation of nucleocytoplasmic transportSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
cell divisionSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
positive regulation of glial cell proliferationSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
mitotic sister chromatid segregationSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (21)

Processvia Protein(s)Taxonomy
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
RNA bindingSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
phosphoprotein phosphatase activitySerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
protein serine/threonine phosphatase activitySerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
protein bindingSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
lamin bindingSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
protein phosphatase 1 bindingSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
phosphatase activitySerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
myosin phosphatase activitySerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
protein kinase bindingSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
protein domain specific bindingSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
protein-containing complex bindingSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
metal ion bindingSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (26)

Processvia Protein(s)Taxonomy
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
chromosome, telomeric regionSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
kinetochoreSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
nucleusSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
nucleolusSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
cytoplasmSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
mitochondrionSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
mitochondrial outer membraneSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
microtubule organizing centerSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
cytosolSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
focal adhesionSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
nuclear speckSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
midbodySerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
cleavage furrowSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
dendritic spineSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
presynapseSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
glutamatergic synapseSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
protein-containing complexSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
PTW/PP1 phosphatase complexSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
nucleusSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
cytoplasmSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID200711Inhibition of Serine/threonine protein phosphatase 1 (PP1) mutants by natural toxins in C127S2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID200718Inhibition of Serine/threonine protein phosphatase 1 (PP1) mutants by natural toxins in R96A2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID200889Exogenous inhibition concentration of Serine/threonine protein phosphatase 5 (PP5)2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID164505Observed inhibition activity of the compounds against protein phosphatases 1 (PP1)1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
A model for binding of structurally diverse natural product inhibitors of protein phosphatases PP1 and PP2A.
AID164502Inhibitory concentration against Protein phosphatase 1 was determined; 0.5-1.02002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
The first two cantharidin analogues displaying PP1 selectivity.
AID200713Inhibition of Serine/threonine protein phosphatase 1 (PP1) mutants by natural toxins in D220V2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID200717Inhibition of Serine/threonine protein phosphatase 1 (PP1) mutants by natural toxins in R221S2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID514321Antimicrobial activity against glc7-129 allele containing Saccharomyces cerevisiae harboring cdc28-as transfected with 2 uM expression vector TEplac195 at 25 nM using deletion pool construction2008Nature chemical biology, Aug, Volume: 4, Issue:8
An integrated platform of genomic assays reveals small-molecule bioactivities.
AID200716Inhibition of Serine/threonine protein phosphatase 1 (PP1) mutants by natural toxins in N124D2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID200749Exogenous inhibition concentration of Serine/threonine protein phosphatase 2C (PP2C); NI means no inhibition.2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID200735Exogenous inhibition concentration of Serine/threonine protein phosphatase 2A (PP2A)2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID200742Exogenous inhibition concentration of Serine/threonine protein phosphatase 2B (PP2B)2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID357839Inhibition of protein phosphatase 2A
AID200715Inhibition of Serine/threonine protein phosphatase 1 (PP1) mutants by natural toxins in H248N2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID200720Inhibition of Serine/threonine protein phosphatase 1 (PP1) mutants by natural toxins in wild type2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID164507Concentration required to inhibit the action of protein phosphatase 2A2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
The first two cantharidin analogues displaying PP1 selectivity.
AID335852Insecticidal activity against Spodoptera littoralis larvae dosed into hemolymph injection measured per 1000 mg of larval body weight measured after 48 hrs2002Journal of natural products, Aug, Volume: 65, Issue:8
Swinhoeiamide A, a new highly active calyculin derivative from the marine sponge Theonella swinhoei.
AID200561Exogenous inhibition of Serine/threonine protein phosphatase 1 (PP1)2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID514322Antimicrobial activity against glc7-127 allele containing Saccharomyces cerevisiae harboring cdc28-as transfected with 2 uM expression vector TEplac195 at 25 nM using deletion pool construction2008Nature chemical biology, Aug, Volume: 4, Issue:8
An integrated platform of genomic assays reveals small-molecule bioactivities.
AID164675Observed inhibition activity of the compounds against protein phosphatases 2A (PP2A)1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
A model for binding of structurally diverse natural product inhibitors of protein phosphatases PP1 and PP2A.
AID200712Inhibition of Serine/threonine protein phosphatase 1 (PP1) mutants by natural toxins in D208A2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID200714Inhibition of Serine/threonine protein phosphatase 1 (PP1) mutants by natural toxins in E275R2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID200719Inhibition of Serine/threonine protein phosphatase 1 (PP1) mutants by natural toxins in Y272F2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (899)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (0.56)18.7374
1990's409 (45.49)18.2507
2000's363 (40.38)29.6817
2010's115 (12.79)24.3611
2020's7 (0.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.32 (24.57)
Research Supply Index6.82 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index54.53 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (38.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews15 (1.64%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other900 (98.36%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]